Valeant goes in search of a remedy with loans in danger of covenant breach

By James Harvey

Tuesday, March 15, 2016

Painkillers won't do - large loan issuer Valeant Pharmaceuticals is going to need something stronger as it looks to stave off a possible default

Subscriber-only article

This article is available only to Creditflux subscribers and free trial users within 30 days of publication.

Already a subscriber? Not logged in? Click here to login.

If you have not already done so,
you may request a FREE TRIAL by clicking here

This trial will give you:
  • 4-weeks' free online access to our
    most recent subscriber-only articles
  • Daily breaking news alert sent by email
  • A print copy of Creditflux

If you currently have a free trial, you will see this message when you try to view articles older than 30 days.

TAGS: Default

Comment by: Anonymous. Posted 8 years ago [2016-03-16 23:46:27]

Valeant is a pharmaceutical that is causing problems rather than curing them. If a CLO manager can sell in the 90's, that strikes me as the wise choice.

Related Stories

CLOs

more stories...